106 related articles for article (PubMed ID: 19712199)
1. Variation in the use of recombinant activated factor VII in critical bleeding.
Willis CD; Cameron PA; Phillips L
Intern Med J; 2010 Jul; 40(7):486-93. PubMed ID: 19712199
[TBL] [Abstract][Full Text] [Related]
2. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
[TBL] [Abstract][Full Text] [Related]
5. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
[TBL] [Abstract][Full Text] [Related]
6. [Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].
Bardon J; Fink J; de Montblanc J; Bergmann JF; Sarrut B; Benhamou D
Ann Fr Anesth Reanim; 2013 Oct; 32(10):659-64. PubMed ID: 23953834
[TBL] [Abstract][Full Text] [Related]
7. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.
Zatta A; Mcquilten Z; Kandane-Rathnayake R; Isbister J; Dunkley S; Mcneil J; Cameron P; Phillips L
Blood Transfus; 2015 Jan; 13(1):86-99. PubMed ID: 24960661
[TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
Flower O; Phillips LE; Cameron P; Gunn K; Dunkley S; Watts A; Rajbhandari D
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):207-15. PubMed ID: 20182351
[TBL] [Abstract][Full Text] [Related]
9. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).
Karkouti K; Arellano R; Aye T; Dupuis JY; Kent B; Lee TW; Lin Y; Ralley F; MacAdams C; Mazer CD; Muirhead B; Rheault MR; Rochon A; Syed S; Waters T; Wong B
Can J Anaesth; 2014 Aug; 61(8):727-35. PubMed ID: 24890696
[TBL] [Abstract][Full Text] [Related]
10. Clinical guidelines and off-license recombinant activated factor VII: content, use, and association with patient outcomes.
Willis CD; Cameron PA; Phillips LE
J Thromb Haemost; 2009 Dec; 7(12):2016-22. PubMed ID: 19804534
[TBL] [Abstract][Full Text] [Related]
11. Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding.
Kandane-Rathnayake RK; Isbister JP; Zatta AJ; Aoki NJ; Cameron P; Phillips LE;
ANZ J Surg; 2013 Mar; 83(3):155-60. PubMed ID: 23035873
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.
Ho KM; Litton E
Transfusion; 2012 Aug; 52(8):1696-702. PubMed ID: 22211634
[TBL] [Abstract][Full Text] [Related]
13. Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland.
Donovan PJ; Iedema J; McLeod DS; Kubler P; Pillans P
ANZ J Surg; 2013 Mar; 83(3):149-54. PubMed ID: 23137066
[TBL] [Abstract][Full Text] [Related]
14. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
15. Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes.
Willis C; Bird R; Mullany D; Cameron P; Phillips L
Vox Sang; 2010 May; 98(4):531-7. PubMed ID: 19878495
[TBL] [Abstract][Full Text] [Related]
16. Identifying and improving unreliable items in registries through data auditing.
Willis CD; Jolley DJ; McNeil JJ; Cameron PA; Phillips LE
Int J Qual Health Care; 2011 Jun; 23(3):317-23. PubMed ID: 21441251
[TBL] [Abstract][Full Text] [Related]
17. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
[TBL] [Abstract][Full Text] [Related]
19. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
[TBL] [Abstract][Full Text] [Related]
20. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
